October 11-15, 2023
Hynes Convention Center
Boston, Massachusetts

Conference Cochairs

Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands (EORTC)

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2023 Molecular Targets and Cancer Therapeutics conference will return to the Hynes Convention Center in Boston. This program attracts 1,200-1,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach to exchange information early in the development process.

AACR STATEMENT REGARDING VENUES FOR THE 2023 ANNUAL MEETING AND OTHER CONFERENCES

The AACR released a statement regarding the venues for the 2023 Annual Meeting and its other conferences in response to recent legislative and political decisions at the state level that may not align with our values.

Read the Statement

SUPPORTER

Sanofi

Poster session Supporters

#Targets23